Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours (Q85753272)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Amir Sabet

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Torjan Haslerud

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Ulrich-Frank Pape

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Amin Sabet

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Frank Grünwald

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Stefan Guhlke

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Hans-Jürgen Biersack

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Samer Ezziddin

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

13 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

number of pages

6

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

205-210

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24030668%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00259-013-2547-z

21 February 2020

exact match

0 references

cites work

Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.

1 reference

12 December 2020

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

1 reference

12 December 2020

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate

1 reference

12 December 2020

End-stage renal disease after treatment with 90Y-DOTATOC.

1 reference

12 December 2020

Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide

1 reference

12 December 2020

Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors

1 reference

12 December 2020

Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats

1 reference

12 December 2020

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

1 reference

12 December 2020

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

1 reference

12 December 2020

A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy

1 reference

12 December 2020

From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging

1 reference

12 December 2020

Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies

1 reference

12 December 2020

Measurement of glomerular filtration rate: single injection plasma clearance method without urine collection

1 reference

12 December 2020

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

12 December 2020

Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial

1 reference

12 December 2020

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

1 reference

12 December 2020

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

1 reference

12 December 2020

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors

1 reference

12 December 2020

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

1 reference

12 December 2020

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

1 reference

12 December 2020

Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours

1 reference

12 December 2020

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

1 reference

12 December 2020

Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

1 reference

12 December 2020

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

1 reference

12 December 2020

Yttrium-90 DOTATOC: first clinical results

1 reference

12 December 2020

Peptide receptor radionuclide therapy

1 reference

12 December 2020

Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.

1 reference

12 December 2020

Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

1 reference

12 December 2020

Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group

1 reference

12 December 2020

Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate

1 reference

12 December 2020

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

12 December 2020

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

1 reference

12 December 2020

Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors

1 reference

12 December 2020

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

1 reference

12 December 2020

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

1 reference

12 December 2020